SureTrader
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

HDG & JL

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
concapk Member Profile
 
Followed By 0
Posts 89
Boards Moderated 0
Alias Born 04/17/13
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 2/1/2018 5:02:21 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/31/2018 5:27:59 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 1/30/2018 8:58:26 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/29/2018 4:08:42 PM
Amarin Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 1/29/2018 4:01:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/23/2018 6:01:14 PM
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events GlobeNewswire Inc. - 1/23/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/17/2018 5:59:57 PM
Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China GlobeNewswire Inc. - 1/17/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/16/2018 6:01:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/9/2018 6:01:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2018 4:57:25 PM
Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook GlobeNewswire Inc. - 1/4/2018 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/2/2018 4:34:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/2/2018 4:33:51 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 12/22/2017 4:13:13 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/21/2017 4:04:15 PM
Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018 GlobeNewswire Inc. - 12/19/2017 6:00:00 AM
Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco GlobeNewswire Inc. - 12/18/2017 4:30:00 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 12/4/2017 4:48:02 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/4/2017 9:04:12 AM
Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular ... GlobeNewswire Inc. - 11/14/2017 4:30:00 PM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Pat... GlobeNewswire Inc. - 11/13/2017 4:30:00 PM
Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical ... GlobeNewswire Inc. - 11/13/2017 6:00:00 AM
Amarin to Present at the Jefferies London Healthcare Conference GlobeNewswire Inc. - 11/7/2017 6:00:00 AM
concapk   Thursday, 10/05/17 07:58:29 PM
Re: Biobillionair post# 115582
Post # of 122823 
HDG & JL

Please understand their are many ways to view situations. I for one agree with Bio that the FDA did point blank screw us back on Oct 13th.

Both of you look at it from a medical viewpoint which you are 100% correct. The FDA realized their mistake and found ways to circumvent the situation not to give AMARIN 35 million potential subscribers without positive results concerning trig lowering to lowering cvd events.

I look at it from a business viewpoint as does BIO that the FDA set up and agreed to an SPA with AMARIN. AMARIN was, an is a small company required to run a 7000 modified to an 8000 CVOT study costing approx. $250/300 million.
This study called REDUCE-IT would take approx. 4 years to complete and that cost would be mitigated by sales from ANCHOR approval. The FDA knew that they would be harming AMARIN by rescinding the SPA, "THEY DIDN'T CARE".

They could have modified the SPA 6 months prior to the ADCOM as Bio has stated. Hdg you said maybe AMARIN was informed and proceeded anyway, which could be true. I think the FDA hedged their situation through out the process knowing the power they haD (my opinion).

Now we are 4 years into the study near the end with double the number of shares from approx 170 to 340 million potentially issued. Those shares paid for REDUCE-IT hurting all original investors.

YES, this is now water under the bridge with results forthcoming. YES, we need to put this behind us and look to the bright future ahead. But as investors, we were hurt badly with many of us still under water so to say. PLEASE don't give the FDA any positive credence for what they did.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist